Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns
XenonXenon(US:XENE) Reuters·2026-09-18 04:38

核心观点 - Xenon Pharmaceuticals因在抑郁症和双相情感障碍的临床试验中出现副作用,暂停了新的患者入组 [1] 临床试验暂停 - Xenon暂停了针对抑郁症和双相情感障碍的临床试验中新的患者入组 [1] - 暂停原因是出现了副作用问题 [1]

Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns - Reportify